Meet the two treatments withdrawn from the market by the FDA for not working against omicron

Eliminating treatments avoids exposing patients to side effects.


The Food and Drug Administration withdrawn from the market two treatments on the list of approved drugs against covid-19 because they are not effective against the omicron variant.

The FDA reported that it withdrew its authorization for the use of Bamlivimab and Etesevimab, from the pharmaceutical company Eli Lilly- and REGEN-COV, made up of Casirivimab and Imdevimab, from Regeneron.

"The data show that these treatments are highly unlikely to be active against the omicron variant, which is expanding rapidly in the United States," Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a statement. .

As of now, those drugs "are no longer authorized for use in any US state, territory, or jurisdiction."

“In the future, if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments, their use in those regions could be licensed,” Cavazzoni added.

The omicron variant accounts for more than 99% of covid-19 cases in the United States, according to data from the Centers for Disease Control and Prevention (CDC).

Eliminating treatments "avoids exposing patients to side effects, such as injection site reactions or allergic reactions that can be potentially serious" in patients infected with omicron, explained the doctor.

The FDA recalled that there are several treatments authorized in the country that are expected to work against the omicron variant in the case of patients who are at risk of developing severe disease, citing among them Paxlovid, Sotrovimab, Veklury (Remdesivir) and Molnupiravir.

The agency followed the recommendation of a committee of the National Institutes of Health (NIH), which last week advised against the use of Eli Lilly and Regeneron therapies, considering that they had a "remarkably reduced" effect against omicron.

Author Profile

Nathan Rivera
Allow me to introduce myself. I am Nathan Rivera, a dedicated journalist who has had the privilege of writing for the online newspaper Today90. My journey in the world of journalism has been a testament to the power of dedication, integrity, and passion.

My story began with a relentless thirst for knowledge and an innate curiosity about the events shaping our world. I graduated with honors in Investigative Journalism from a renowned university, laying the foundation for what would become a fulfilling career in the field.

What sets me apart is my unwavering commitment to uncovering the truth. I refuse to settle for superficial answers or preconceived narratives. Instead, I constantly challenge the status quo, delving deep into complex issues to reveal the reality beneath the surface. My dedication to investigative journalism has uncovered numerous scandals and shed light on issues others might prefer to ignore.

I am also a staunch advocate for press freedom. I have tirelessly fought to protect the rights of journalists and have faced significant challenges in my quest to inform the public truthfully and without constraints. My courage in defending these principles serves as an example to all who believe in the power of journalism to change the world.

Throughout my career, I have been honored with numerous awards and recognitions for my outstanding work in journalism. My investigations have changed policies, exposed corruption, and given a voice to those who had none. My commitment to truth and justice makes me a beacon of hope in a world where misinformation often prevails.

At Today90, I continue to be a driving force behind journalistic excellence. My tireless dedication to fair and accurate reporting is an invaluable asset to the editorial team. My biography is a living testament to the importance of journalism in our society and a reminder that a dedicated journalist can make a difference in the world.